Source comparison
Growth Hormone Secretagogues vs Exogenous HGH
Growth hormone secretagogues (GHS) don't deliver growth hormone. They trigger the pituitary to produce and release it endogenously. Exogenous recombinant human growth hormone (rhGH) bypasses the pituitary entirely, introducing synthetic somatropin directly int
This comparison does not assign a generated winner or score.
- Growth hormone secretagogues (GHS) don't deliver growth hormone. They trigger the pituitary to produce and release it endogenously. Exogenous recombinant human growth hormone (rhGH) bypasses the pituitary entirely, introducing synthetic somatropin directly into circulation. The mechanistic difference is the foundation of every downstream distinction in receptor dynamics, side effect profiles, and research application.
- GHRH analogs like CJC-1295 with ipamorelin bind to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary, stimulating endogenous GH secretion in pulsatile waves that mirror natural circadian rhythm. Ghrelin mimetics like ipamorelin and hexarelin bind to ghrelin receptors (GHS-R1a) on the same cells, amplifying both the amplitude and frequency of GH pulses. MK-677 (ibutamoren) is an orally active non-peptide ghrelin receptor agonist with a 24-hour half-life, allowing once-daily dosing that sustains elevated GH and IGF-1 across the full circadian cycle.
- Exogenous HGH delivers supraphysiological GH concentrations that don't pulse. They flood. The pituitary's negative feedback loop suppresses endogenous production when circulating GH remains elevated beyond normal pulse duration, which is why chronic rhGH use can lead to pituitary atrophy over time. Secretagogues preserve the feedback loop because they work within it rather than overriding it. IGF-1 levels rise, but they rise proportionally to the body's amplified natural secretion, not to an externally imposed pharmacological dose.
- For labs studying metabolic signaling or anabolic pathways without inducing full pituitary suppression, secretagogues offer a controllable middle ground. The HGH alternative peptides 2026 update reflects broader adoption of stacking protocols. CJC-1295 with ipamorelin is the most studied combination because GHRH receptor stimulation and ghrelin receptor stimulation synergise without receptor desensitisation. Research from the Journal of Clinical Endocrinology & Metabolism showed that combining GHRH analogs with ghrelin mimetics produced 3–5× greater GH release amplitude compared to either compound alone, without increasing cortisol or prolactin levels beyond baseline variation.